Metaprot and succinic acid in acute hypoxia in mice
V. D. Dekkanova, V. R. Danilov, M. S. Polyakova · 2016 · Bulletin of Medical Internet Conferences. Vol. 5, no. 12, p. 1770. Posted 30 January 2016.
Indexed 2026-11-11.
Related evidence maps: Military & occupational ↗
Reported findings and study design
Reported findings
Four groups of 10 mice received control, Metaprot, succinic acid or their combination. Each active ingredient was given intragastrically at 50 mg/kg. The endpoint was survival time in the acute hypoxia model.
Dose, route and schedule
Each active agent was administered intragastrically at 50 mg/kg. The combination used 50 mg/kg of each agent.
Protocol source ↗ · Conference abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Combination vs control | 18.8% longer survival time | Reported p ≤ 0.05 vs control. |
| Metaprot vs control | 16.1% longer survival time | Reported p ≤ 0.05 vs control. |
| Succinic acid vs control | 14.9% longer survival time | No p value supplied. |
The combination exceeded the Metaprot estimate by 2.7 percentage points. A difference between those arms and a synergistic interaction were not established.
Source for these results ↗ · Reviewed 2026-11-11
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The abstract gives no absolute survival times, uncertainty intervals, direct combination-versus-monotherapy test or formal interaction test.
- Related proceedings versions should be treated as the same experiment.
Source access
Original conference abstract and the reported comparisons checked.
Source reviewed 2026-11-11.
Source type: Conference abstract
Citation and original source
Original source: V. D. Dekkanova, V. R. Danilov, M. S. Polyakova. Metaprot and succinic acid in acute hypoxia in mice Bulletin of Medical Internet Conferences. Vol. 5, no. 12, p. 1770. Posted 30 January 2016. 2016.
Molekul research summary: https://molekul.io/research/dekkanova-metaprot-succinic-acid-2016. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Bemitil
A benzimidazole-derived actoprotector, also indexed as bemethyl and Metaprot. Research spans patient asthenia, occupational settings, neuromuscular and liver studies, metabolism and preclinical safety; these are research contexts, not established uses.
Succinic acid
A metabolic substrate tested alone and with Metaprot in a small mouse hypoxia experiment. The study used succinic acid, distinct from Bemitil succinate or mixed succinate salts.